Abstract
摘要
相似文献
1
PDPs see increases in cost-sharing amounts.
Manag Care. 2009 Aug;18(8):55.
2
Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7.
3
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Issue Brief Health Policy Track Serv. 2009 Jan 5:1-26.
4
Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-32.
5
Medicare program; Medicare Advantage and prescription drug benefit programs: negotiated pricing and remaining revisions. Final rule with comment period.
Fed Regist. 2009 Jan 12;74(7):1493-549.
6
Can a pharmacist reduce annual costs for Medicare Part D enrollees?
Consult Pharm. 2011 Mar;26(3):182-9. doi: 10.4140/TCP.n.2011.182.
7
Medicare Part D update--lessons learned and unfinished business.
N Engl J Med. 2009 Jul 23;361(4):406-14. doi: 10.1056/NEJMhpr0809949.
8
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Issue Brief Health Policy Track Serv. 2008 Jan 7:1-23.
9
Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
Res Social Adm Pharm. 2010 Jun;6(2):85-9. doi: 10.1016/j.sapharm.2010.04.004.
10
Primary care and prescription drugs: coverage, cost-sharing, and financial protection in six European countries.
Issue Brief (Commonw Fund). 2010 Mar;82:1-14.
Zotero 插件